DY 268 is a farnesoid X receptor (FXR) antagonist (IC50 = 7.5 nM in a time-resolved FRET assay).[1] It inhibits FXR transactivation in a cell-based assay with an IC50 value of 468 nM.
Reference:
[1]. Yu, D.D., Lin, W., Forman, B.M., et al. Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor. Bioorg. Med. Chem. 22(11), 2919-2938 (2014).
















